GODREJAGRO Godrej Agrovet Q4 FY25 results (Jan–Mar 2025) and concall
Godrej Agrovet reported a mixed FY25, with standout performances in its core Animal Feed, Crop Protection, and Vegetable Oil segments driving record profitability for the standalone entity. However, this was significantly offset by a challenging year at subsidiary Astec LifeSciences, which posted a major loss. Management has laid out a cautious recovery plan for Astec and expects strong, volume-led growth of 16-18% for the consolidated entity in FY26, supported by margin expansion in the Dairy business and a rebound in key segments. Strategic portfolio restructuring is also under consideration
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 1,848 | 1,869 | 1,550 |
| EBITDA | 222 | 195 | 130 |
| Net profit | 132 | 166 | 68 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
